

UNCLASSIFIED

AD NUMBER
ADB269116
NEW LIMITATION CHANGE
TO Approved for public release, distribution unlimited
FROM Distribution authorized to U.S. Gov't. agencies only; Proprietary Info.; Jun 2001. Other requests shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott St., Fort Detrick, MD 21702-5012.
AUTHORITY
USAMRMC ltr, dtd 21 Feb 2003

THIS PAGE IS UNCLASSIFIED

AD_____

Award Number: DAMD17-99-1-9308

TITLE: Differential Activation of p53 Target Genes in Breast Cancer

PRINCIPAL INVESTIGATOR: Edward Thornborrow
James Manfredi, Ph.D.

CONTRACTING ORGANIZATION: Mount Sinai School of Medicine
New York, New York 10029

REPORT DATE: June 2001

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, June 2001). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20010810 080

NOTICE

USING GOVERNMENT DRAWINGS, SPECIFICATIONS, OR OTHER DATA INCLUDED IN THIS DOCUMENT FOR ANY PURPOSE OTHER THAN GOVERNMENT PROCUREMENT DOES NOT IN ANY WAY OBLIGATE THE U.S. GOVERNMENT. THE FACT THAT THE GOVERNMENT FORMULATED OR SUPPLIED THE DRAWINGS, SPECIFICATIONS, OR OTHER DATA DOES NOT LICENSE THE HOLDER OR ANY OTHER PERSON OR CORPORATION; OR CONVEY ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE, OR SELL ANY PATENTED INVENTION THAT MAY RELATE TO THEM.

LIMITED RIGHTS LEGEND

Award Number: DAMD17-99-1-9308
Organization: Mount Sinai School of Medicine

Those portions of the technical data contained in this report marked as limited rights data shall not, without the written permission of the above contractor, be (a) released or disclosed outside the government, (b) used by the Government for manufacture or, in the case of computer software documentation, for preparing the same or similar computer software, or (c) used by a party other than the Government, except that the Government may release or disclose technical data to persons outside the Government, or permit the use of technical data by such persons, if (i) such release, disclosure, or use is necessary for emergency repair or overhaul or (ii) is a release or disclosure of technical data (other than detailed manufacturing or process data) to, or use of such data by, a foreign government that is in the interest of the Government and is required for evaluational or informational purposes, provided in either case that such release, disclosure or use is made subject to a prohibition that the person to whom the data is released or disclosed may not further use, release or disclose such data, and the contractor or subcontractor or subcontractor asserting the restriction is notified of such release, disclosure or use. This legend, together with the indications of the portions of this data which are subject to such limitations, shall be included on any reproduction hereof which includes any part of the portions subject to such limitations.

THIS TECHNICAL REPORT HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION.

Carol B. Christian

7-23-01

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE June 2001	3. REPORT TYPE AND DATES COVERED Annual Summary (1 May 00 - 1 May 01)
4. TITLE AND SUBTITLE Differential Activation of p53 Target Genes in Breast Cancer			5. FUNDING NUMBERS DAMD17-99-1-9308
6. AUTHOR(S) Edward Thornborrow James Manfredi, Ph.D.			
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Mount Sinai School of Medicine New York, New York 10029 Email - et@doc.mssm.edu			8. PERFORMING ORGANIZATION REPORT NUMBER
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER
11. SUPPLEMENTARY NOTES			
12a. DISTRIBUTION / AVAILABILITY STATEMENT Distribution authorized to U.S. Government agencies only (proprietary information, June 2001). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.			12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words)			

A significant percentage of breast tumors are resistant to apoptotic stimuli. This resistance has been correlated with decreased expression of the proapoptotic protein *bax*. A major regulator of *bax* expression is the tumor suppressor p53. Unlike other well characterized p53 response elements, like the *p21-5'* element, which consist of two consensus p53 half-sites, the response element of the human *bax* promoter consists of three half-sites that cooperate in mediating p53-dependent transactivation. Within this unique response element are six GC-rich base pairs that mediate an interaction with Sp1 both *in vitro* and in cells. These bases were found to be required for p53-dependent activation, and mutations that inhibited Sp1 binding also blocked the ability of p53 to activate transcription through this element, suggesting a model in which p53 requires the cooperation of Sp1 or a Sp1-like factor to mediate transcriptional activation of the human *bax* promoter. In addition, I recently identified a novel p53 response element conserved in the first intron of both the human and the murine *bax* genes. This element is required for the p53-dependent transcriptional activation of both the human and murine *bax* genes, demonstrating that *bax* is a direct and evolutionarily conserved transcriptional target of p53.

14. SUBJECT TERMS Breast Cancer			15. NUMBER OF PAGES 43
			16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

Table of Contents

Cover.....	
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	7
Reportable Outcomes.....	7
Conclusions.....	8
References.....	8
Appendices.....	9

Differential Activation of p53 Target Genes in Breast Cancer

Introduction:

In the past decade, there have been great advances in the field of breast cancer. These advances largely have been in the fields of education and early detection. Unfortunately, however, the treatment of breast cancer continues to be problematic in that a significant proportion of tumors are resistant to chemotherapy. Evidence suggests that this resistance is due to a defect in the normal programmed cell death or apoptotic pathway. A complete understanding of the apoptotic mechanism, therefore, is essential for designing the most therapeutic regimen for the treatment of breast cancer. The protein bax is a key regulator of the apoptotic process, and low levels of this protein correlate with a decreased response to treatment and a decreased survival period in breast cancer patients. A major regulator of bax transcription is the tumor suppressor protein p53, and the work I am conducting in this fellowship addresses the transcriptional regulation of the *bax* gene by p53. As such, I hope to understand the mechanism by which bax levels are reduced in breast tumor cells, and then to use this information to elevate the level of activation of the *bax* gene, causing breast tumors to become sensitive to apoptotic stimuli like chemotherapy. I believe that completion of the work proposed in this fellowship will enhance our understanding of both the origins of breast cancer and how tumors respond to treatment. In addition, I believe this work will identify novel targets for therapeutic intervention in breast tumors that are otherwise resistant to current treatment.

Body:

A significant percentage of breast tumors have been shown to be resistant to apoptotic stimuli such as chemotherapeutic drugs. This resistance has been correlated with a decreased expression of the proapoptotic protein bax. Low bax levels have been associated with a decreased treatment response and a shorter survival time in women with metastatic breast adenocarcinoma. In addition, overexpression of bax in tumor cell lines sensitizes the cells to drug-induced apoptosis. A major regulator of *bax* expression is the tumor suppressor p53. p53 is a well-characterized transcription factor that can bind DNA in a sequence specific manner and activate the transcription of particular genes, including *bax*. When compared to alternate p53 targets such as the cyclin dependent kinase inhibitor *p21*, several lines of evidence suggest that the *bax* gene is differentially regulated by p53. Preliminary data presented in the fellowship application demonstrated that the breast carcinoma MCF-7 and MDA-MB-453 cell lines both exhibited a defect in the ability of wild-type p53 to activate transcription through both the intact *bax* promoter as well as the p53 response element in isolation from the promoter. This defect was specific for *bax* as p53 was capable of activating transcription of other p53-dependent target genes, such as the cyclin-dependent kinase inhibitor *p21*. The goal of the work being conducted

Differential Activation of p53 Target Genes in Breast Cancer

in this fellowship is to understand the molecular mechanism by which wild-type p53 selectively fails to activate the transcription of the pro-apoptotic *bax* gene.

Work on this project began by identifying the minimal sequence within the *bax* promoter required to mediate p53-dependent transactivation. In contrast to other well characterized p53 response elements, which consist of two copies (half-sites) of sequences that closely resemble the palendromic decamer 5'-RRRCWWGYYY-3' (where R is a purine, Y is a pyrimidine, and W is an adenine or threonine) separated from each other by 0-13 bases, the minimal element from the *bax* promoter consists of three copies of this sequence, or three half-sites. Using this minimal sequence as a probe in electrophoretic mobility shift assays (EMSAs) with nuclear extract, a factor was identified that demonstrates marked sequence specificity for this p53 response element. This factor, referred to as BBF (Bax Binding Factor) in the original fellowship application, is specific for the p53-response element of *bax* as it fails to bind other well-characterized p53-response elements, including that of the cyclin-dependent kinase inhibitor *p21* (Thornborrow and Manfredi, 1999). Five tasks were proposed in the original fellowship application to address the biological role of this binding factor in both breast tumor formation and resistance to treatment: 1) Identify additional wild-type p53 breast cancer cell lines that fail to activate transcription of the *bax* gene and fail to undergo p53-dependent apoptosis in response to DNA damage; 2) Explore a possible correlation between BBF levels and a cell line's ability to activate transcription of the *bax* gene and to undergo p53-dependent apoptosis; 3) Purify and clone BBF; 4) Determine the relevance of BBF to the apoptotic response in relevant breast cell model systems; 5) Examine the potential correlation between BBF levels, *bax* levels, and p53 status in breast tumor biopsy samples as compared to normal mammary epithelium.

Work on Task #3 successfully identified BBF as the transcription factor Sp1 (see Appendix 1). Mutational analysis demonstrated that the binding of Sp1 to the *bax* promoter is mediated by six base pairs (5'-GGGCGT-3') in the p53 half-site most proximal to the start site of transcription (Figure 4). Further, it was shown that the minimal response element capable of mediating p53-dependent transcriptional activation consists of the two distal p53 half-sites plus this adjacent six base pairs (Figure 8). This GC-rich region constitutes a "GC-box" capable both of binding members of the Sp family of transcription factors, including Sp1 *in vitro* (Figures 3 and 4), and of conferring Sp1-dependent transcriptional activation on a minimal promoter in cells (Figure 5). Mutations within this GC-box abrogated the ability of p53 to activate transcription without affecting the affinity of p53 for its binding site (Figures 6 and 8), demonstrating that these six bases are required for p53-dependent activation. In addition, a positive correlation was observed between the ability of p53 to activate transcription in cells and the ability of Sp1 to bind this response element *in vitro* (Figures 6 and 8). Mutations that inhibited Sp1 binding also blocked the ability of p53 to activate transcription through this element. Together, these results

Differential Activation of p53 Target Genes in Breast Cancer

suggest a model in which p53 requires the cooperation of Sp1 or a Sp1-like factor to mediate transcriptional activation of the human *bax* promoter (Figure 9).

Two independent reports recently demonstrated that the murine *bax* promoter is unresponsive to p53 in transient transfection assays (Igata et al., 1999, Schmidt et al., 1999), suggesting a lack of evolutionary conservation with respect to the ability of p53 to transcriptionally regulate *bax* expression, and questioning the significance of the above studies done with the human *bax* promoter. To assay for additional sequence elements that influence p53-dependent transcriptional activation, extended pieces of both the human and murine *bax* genes were cloned (see Appendix 2). Sequence analysis of these two genes identified two regions conserved between human and mouse (Figure 1). The first region corresponds to the previously characterized p53 response element in the human *bax* promoter at -113 to -83 from the start site of transcription. The second region of conservation is found in the first intron of both genes and resembles the p53 DNA-binding consensus sequence. Both regions in the human and murine *bax* genes were capable of binding p53 in a sequence specific manner *in vitro* (Figures 1 and 3) and of conferring p53 responsiveness upon a minimal promoter in cells (Figures 2 and 3). Further, it was found that the p53 response element in the first intron of the human and murine *bax* genes is both required and sufficient for p53-dependent transcriptional activation in the context of a transient assay (Figures 2 and 4). These results demonstrate that *bax* is a direct and evolutionarily conserved transcriptional target of p53.

The studies characterizing the novel p53 response element in the first intron of both the human and murine *bax* genes are a digression from the original Statement of Work. These experiments, however, are essential to validate the significance of the work done with the human *bax* promoter. As such, I propose the addition of a new task to my statement of work. Prior to continuing with the original tasks, it is important to determine the relevance of both the promoter and intronic response elements to the p53-dependent upregulation of endogenous *bax* expression in response to physiological stresses like DNA damage. To this end, I will utilize the ML-1 cell line which is known to respond to DNA damage with a p53-dependent upregulation of *bax*. Both *in vivo* footprinting and chromatin immunoprecipitation will be used to assay for occupancy of both the promoter and intronic p53 response elements following damage. Once it is established that either one or both of these elements is required for p53-dependent upregulation of *bax* expression, then subsequent questions concerning the potential role of coactivating elements as well as possible mechanisms of p53 action, including roles in chromatin remodeling and/or transcriptional elongation, can be addressed.

In addition to the above research accomplishments, I have continued to enhance my academic training and educational experience. While my course work is complete, I continue to participate in a weekly journal club, research seminar, and student club, each focussing on issues that are particularly relevant to the topics of tumor formation and progression. Also, I have had

Differential Activation of p53 Target Genes in Breast Cancer

the opportunity to attend international scientific meetings, including the 91st Annual Meeting of the American Association for Cancer Research and the 10th International p53 Workshop, both of which have allowed me to interact with renowned scientists in the field of tumor biology, and to learn of the latest developments in the field. To be properly prepared for a successful career in the battle against breast cancer one should be familiar with both the history of research as well as the most current techniques used in the field. I believe that the work I am conducting is so intimately connected to both the origins and the treatment of breast cancer that it will provide me with the broad foundation of knowledge and technical skill that will allow me to continually identify important clinical aspects of breast cancer that can benefit from further scientific research. As an M.D./Ph.D. student at the Mount Sinai School of Medicine I am receiving specialized training that will allow me to traverse both the clinical and basic science worlds. To this point, I participate in a program in which I spend one afternoon a week doing patient care work. The research I am conducting in the laboratory is an essential compliment to my clinical training that will continue to provide me with the skills to decrease the gap between benchtop discoveries and bedside cures. The experience of designing my research project and scrutinizing my experimental data is helping me to develop the analytical skills and experience necessary for a productive future battling breast cancer.

Key Research Accomplishments:

- Identified minimal p53 responsive element in the human *bax* promoter.
 - Found the response element to be unique in that it consists of three p53 half-sites instead of the typical two.
- Demonstrated that p53 requires Sp1 or an Sp1-like cofactor to mediate transcriptional activation of the human *bax* promoter.
- Identified a novel p53 response element perfectly conserved in the first intron of both the human and murine *bax* genes.
 - Demonstrated that this element is both required and sufficient for the p53-dependent transcriptional activation of *bax*.

Reportable Outcomes:

Edward C. Thornborrow and James J. Manfredi (2001) The Tumor Suppressor Protein p53 Requires a Cofactor to Activate Transcriptionally the Human *BAX* Promoter, *Journal of Biological Chemistry* **276**: 15598-15608.

Differential Activation of p53 Target Genes in Breast Cancer

Edward C. Thornborrow, Elissa M. Schwartzfarb, and James J. Manfredi (2001) A conserved intronic response element mediates direct p53-dependent transcriptional activation of both the human and murine *bax* genes, (In Preparation).

Conclusions:

Low levels of bax protein correlate with a decreased response to treatment and a decreased survival period in breast cancer patients. A major regulator of *bax* transcription is the tumor suppressor protein p53. The work conducted during this fellowship has analyzed in detail the interaction of p53 with the *bax* gene, and demonstrated that p53 requires both a cofactor to function through the *bax* promoter and a newly identified intronic response element to function in the context of the *bax* gene. Both of these observations suggest novel mechanisms to explain the defect in p53-depedent *bax* expression and apoptosis observed in many breast tumors. I believe that completion of the work proposed in this fellowship will enhance our understanding of both the origins of breast cancer and how tumors respond to treatment. In addition, I believe this work may identify novel targets for therapeutic intervention in breast tumors that are otherwise resistant to current treatment. Perhaps more significantly, this fellowship has allowed me to obtain an exceptional education that will form the basis for a continuing career in the battle against breast cancer.

References:

- Igata, E., Inoue, T., Ohtani-Fujita, N., Sowa, Y., Tsujimoto, Y. and Sakai, T. (1999) *Gene*, 238, 407-415.
- Schmidt, T., Korner, K., Karsunky, H., Korsmeyer, S., Muller, R. and Moroy, T. (1999) *Cell Death Differ*, 6, 873-882.
- Thornborrow, E. C. and Manfredi, J. J. (1999) *J Biol Chem*, 274, 33747-33756.

Differential Activation of p53 Target Genes in Breast Cancer

Appendices:

Appendix 1: "The Tumor Suppressor Protein p53 Requires a Cofactor to Activate Transcriptionally the Human *BAX* Promoter"

Appendix 2: "A conserved intronic response element mediates direct p53-dependent transcriptional activation of both the human and murine *bax* genes"

The Tumor Suppressor Protein p53 Requires a Cofactor to Activate Transcriptionally the Human *BAX* Promoter*

Received for publication, December 22, 2000
Published, JBC Papers in Press, February 13, 2001, DOI 10.1074/jbc.M011643200

Edward C. Thornborrow and James J. Manfredi†

From The Derald H. Ruttenberg Cancer Center, Mount Sinai School of Medicine, New York, New York 10029

An important regulator of the proapoptotic *BAX* is the tumor suppressor protein p53. Unlike the *p21* gene, in which p53-dependent transcriptional activation is mediated by a response element containing two consensus p53 half-sites, it previously was reported that activation of the *BAX* element by p53 requires additional sequences. Here, it is demonstrated that the minimal *BAX* response element capable of mediating p53-dependent transcriptional activation consists of two p53 half-sites plus an adjacent 6 base pairs (5'-GGGCGT-3'). This GC-rich region constitutes a "GC box" capable both of binding members of the Sp family of transcription factors, including Sp1 *in vitro*, and of conferring Sp1-dependent transcriptional activation on a minimal promoter in cells. Mutations within this GC box abrogated the ability of p53 to activate transcription without affecting the affinity of p53 for its binding site, demonstrating that these 6 bases are required for p53-dependent activation. In addition, a positive correlation was observed between the ability of p53 to activate transcription in cells and the ability of Sp1 to bind this response element *in vitro*. Mutations that inhibited Sp1 binding also blocked the ability of p53 to activate transcription through this element. Together, these results suggest a model in which p53 requires the cooperation of Sp1 or a Sp1-like factor to mediate transcriptional activation of the human *BAX* promoter.

The BCL-2 family of proteins are key mediators of the apoptotic response. One member of this family is the proapoptotic *BAX*. Preceding apoptosis, cytosolic *BAX* translocates to the mitochondria and homodimerizes. Homodimeric *BAX* then is thought to cause the release of cytochrome *c* (1–3) which subsequently functions as a coactivator of Apaf-1 in the cleavage of pro-caspase-9, initiating programmed cell death (4). *BAX* exists in equilibrium with two of its homologs, BCL-2 and BCL-X_L. Unlike *BAX*, these two homologs exert antiapoptotic effects by heterodimerizing with *BAX* in the mitochondria, blocking its ability to release cytochrome *c* (5, 6). Thus, an important determinant of the apoptotic response of a cell is the balance between the levels of *BAX* and BCL-2/BCL-X_L. In this regard, regulation of the level of expression of *BAX* protein is key.

* This work was supported by NCI Grant CA69161 from the National Institutes of Health and the Breast Cancer Program of the United States Army Medical Research and Materiel Command Grants DAMD-17-97-1-7336, DAMD-17-97-1-7337, and DAMD-17-99-1-9308. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

† To whom correspondence should be addressed: Cancer Center, Box 1130, Mount Sinai School of Medicine, New York, NY 10029. Tel.: 212-659-5495; Fax: 212-849-2446.

An important regulator of *BAX* gene expression is the tumor suppressor protein p53 (7, 8). The p53 protein has been implicated in several growth-related pathways, including apoptosis and cell cycle arrest (9, 10). The ability of p53 to function as a sequence-specific DNA-binding protein appears to be central to its role as a tumor suppressor (11, 12). At its amino terminus, the protein contains a potent transcriptional activation domain (13) that is linked to a central core domain that mediates sequence-specific DNA binding (14–16). Both of these domains have been shown to be important for p53-mediated growth suppression (17).


A DNA consensus sequence through which p53 binds and activates transcription has been identified. This sequence consists of two palindromic decamers of 5'-RRRCWWGYYY-3' (where R is a purine; Y is a pyrimidine; and W is an adenine or thymine) separated by 0–13 base pairs, forming four repeats of the pentamer 5'-RRRCW-3' alternating between the top and bottom strands of the DNA duplex (18, 19). Through sequences similar to this consensus, p53 has been shown to activate the transcription of many genes, including *BAX*, *p21*, *mdm2*, *gadd45*, *IGF-BP3*, and *cyclin G* (8, 20–26). When compared with alternate p53 targets, studies demonstrate that the *BAX* gene is differentially regulated by wild-type p53 in a cell type-specific manner (7, 27, 28). In the mouse, p53-dependent regulation of *BAX* expression following ionizing radiation is seen in the prostate, thymus, spleen, small intestine, and lung, as well as sympathetic, Purkinje, and olfactory cortical neurons. In the kidney, heart, liver, and brain, however, no p53-dependent regulation of *BAX* is observed (7, 27). Furthermore, the myeloid leukemia ML-1, Burkitt's lymphoma WMN and AG876, and lymphoblastoid NL2 and FWL cell lines induce *BAX* following ionizing radiation, whereas the fibroblast AG1522 and WI38, colorectal carcinoma RKO, and osteosarcoma U2-OS cell lines fail to do so (28). In addition, several tumor-derived p53 mutants have been identified that are capable of activating transcription through the promoter of the *p21* gene but not through the *BAX* promoter (29–32). This correlates with an inability of these mutants to trigger apoptosis (29, 31, 32), suggesting that a failure in the ability of p53 to transactivate the *BAX* gene may play an important role in tumor formation and progression. Supporting this, Yin *et al.* (33) demonstrated that *BAX* is an obligatory downstream effector for the p53-mediated apoptosis that attenuates choroid plexus tumor growth in the TgT121 mouse model. Thus, a complete understanding of the transcriptional regulation of the *BAX* promoter by p53 may yield important information relevant to our understanding of tumorigenesis.

Here is presented a detailed analysis of the p53 response element located in the promoter of the human *BAX* gene. The minimal *BAX* response element capable of mediating p53-dependent transcriptional activation is found to consist of two p53 half-sites plus an adjacent 6 base pairs (5'-GGGCGT-3') that

Electrophoretic Mobility Shift Assay—Production of baculovirus-infected Sf9 cell extracts and purification of recombinant human p53 protein were done as described previously (34). Purified p53 protein,

¹ The abbreviations used are: PCR, polymerase chain reaction; DTT, dithiothreitol; EMSA, electrophoretic mobility shift assays.

FIG. 1. All three potential p53 half-sites are required for the p53-dependent transcriptional activation of the human BAX promoter. A and B, Saos-2 cells were transfected as described under "Experimental Procedures" with 1 μ g of the indicated pBAX reporter constructs in the presence of either 10 ng of pCMV-p53^{wt} (white bars) or 10 ng of pCMV-p53^{mut} (gray bars). 24 h post-transfection cells were lysed and assayed for total protein and luciferase activity as described under "Experimental Procedures." The indicated values are the average of three independent experiments each performed in duplicate. Error bars correspond to one S.D. The numbers above each bar indicate the fold activation for each reporter construct observed with pCMV-p53^{wt} as compared with pCMV. A, the previously identified p53 response element is indicated by the dark gray box at -113 to -83. B, the three potential p53 half-sites are represented by the light gray (-113 to -104), white (-102 to -93), and dark gray (-92 to -83) boxes.



extract from Sf9 cells expressing recombinant human Sp1 protein, or HeLa cell nuclear extract was incubated with 3 ng of radiolabeled double-stranded oligonucleotide and antibody (Sp1 PEP-2X, p300 N-15X, and CBP 451X, Santa Cruz Biotechnology), where appropriate, in a total volume of 30 μ l of DNA binding buffer (20 mM HEPES, pH 7.5, 83 mM NaCl, 0.1 mM EDTA, 12% glycerol, 2 mM MgCl₂, 2 mM spermidine, 0.7 mM DTT, and 17 μ g/ml poly(dI-dC)) for 20 min at room temperature. Samples were loaded on a native 4% acrylamide gel in 0.5 \times TBE and electrophoresed at 4 $^{\circ}$ C at 225 V for 2 h. The gel was dried and exposed to Kodak XAR film using an intensifying screen at -70 $^{\circ}$ C. Phosphorimaging and densitometry data were collected with a Personal Molecular Imager FX and a GS-710 Calibrated Imaging Densitometer (Bio-Rad), and analyzed with Quantity One software (Bio-Rad).


RESULTS

All Three Potential p53 Half-sites Are Required for the p53-dependent Transcriptional Activation of the Human BAX Promoter—Previously it was demonstrated that in isolation the p53 response element from the human BAX promoter required sequences from three adjacent half-sites to confer p53-dependent transcriptional activation on a minimal promoter (37). To confirm the requirement of all three half-sites in the context of the BAX promoter, luciferase reporter plasmids with various deletions in the BAX promoter, both in and around the p53 response element, were cotransfected with either pCMV or a wild-type p53 expression vector into the p53-negative osteosarcoma Saos-2 cell line (Fig. 1). The previously characterized p53 response element of the BAX promoter is contained within the sequence from -113 to -83 from the start site of transcription.

There was no significant difference between the p53-dependent transactivation of either a reporter construct lacking sequences 5' to the p53 response element (pBAX -127/+51) or the full-length promoter construct (pBAX -315/+51) (Fig. 1A). Deletion of a larger fragment, including the p53 response element (pBAX -76/+51), produced a reporter construct that was unresponsive to wild-type p53 (Fig. 1A). Furthermore, targeted deletion of the promoter region containing the p53 response element (pBAX Δ -126/-77) also produced a reporter plasmid that was unresponsive to wild-type p53 (Fig. 1A). These results show that -113 to -83 is the only region, within the 366-base pair promoter fragment investigated, that affects the ability of p53 to activate transcription.

The region from -113 to -83 contains three potential p53 half-sites (represented in Fig. 1B as the light gray, white, and dark gray boxes). The role of each of these half-sites in the p53-dependent activation of the BAX promoter was examined. Removal of the first half-site from -113 to -104 (pBAX Δ -113/-104) significantly reduced the ability of p53 to activate transcription through this promoter (Fig. 1B, compare 63-fold with pBAX -315/+51 to 7-fold with pBAX Δ -113/-104), whereas removal of the second (pBAX Δ -103/-93) or the third half-site (pBAX Δ -92/-83) completely abolished the ability of p53 to activate transcriptionally the promoter (Fig. 1B). Consistent with the above results, removal of the first and second half-sites in combination (pBAX Δ -113/-93) also abolished the ability of p53 to activate transcriptionally the promoter (Fig. 1B).

FIG. 2. The first two potential p53 half-sites constitute a bona fide p53 response element. Saos-2 cells were transfected as described under "Experimental Procedures" with 1 μ g of the indicated pTATA reporter constructs in the presence of either 10 ng of pCMV (white bars) or 10 ng of pCMV-p53^{wt} (gray bars). 24 h post-transfection cells were lysed and assayed for total protein and luciferase activity as described under "Experimental Procedures." The indicated values are the average of three independent experiments each performed in duplicate. Error bars correspond to 1 S.D. The numbers above each bar indicate the fold activation for each reporter construct observed with pCMV-p53^{wt} as compared with pCMV. The sequence of the BAX promoter from -113 to -83 is given at the top of the figure. Potential p53 quarter-sites are indicated by the solid bars above and below the sequence. Bases that deviate from the p53 DNA-binding consensus sequence are indicated by asterisks. The three potential half-sites are indicated by the brackets labeled 1-3, respectively, and are represented graphically as the light gray, white, and dark gray boxes, respectively. The vertical arrow above the BAX sequence indicates the 1-base pair insert between the first and second half-sites.



These results demonstrate that, as was observed with the isolated response element (37), p53 requires sequences from all three potential half-sites to mediate transcriptional activation of the BAX promoter.

The First Two Potential p53 Half-sites Constitute a Bona Fide p53 Response Element—Each of the three potential p53 half-sites located in the BAX promoter from -113 to -83 closely resembles the consensus sequence of 5'-RRRCWW-GYYY-3' (represented in Fig. 2 by the light gray, white, and dark gray boxes). The first, located at -113 to -104, deviates from the consensus at 2 bases (-113 and -104). The second half-site matches the consensus sequence at all 20 base pairs and is located at -102 to -93. The third half-site is located at -92 to -83 and deviates from the consensus at three bases (-84, -85, and -88) (see Fig. 2). These three half-sites can combine in different ways to produce a total of three possible p53 complete binding sites (half-sites 1 and 2, 2 and 3, and 1 and 3). Previous studies demonstrated that in electrophoretic mobility shift assays (EMSA), double-stranded oligonucleotides representing both -113 to -93 (half-sites 1 and 2) and -102 to -83 (half-sites 2 and 3) are capable of binding p53 in a sequence-specific manner with similar affinities (37). When cloned upstream of the adenovirus *E1b* minimal promoter in the pTATA luciferase reporter plasmid, however, the combination of the first and second half-sites (-113 to -93) is unable to mediate p53-dependent transcriptional activation (37). To examine further the ability of p53 to interact with this sequence in cells, the -113 to -93 sequence was multimerized (as three copies) and cloned into the pTATA luciferase reporter plasmid. This reporter plasmid was cotransfected with either pCMV or a wild-type p53 expression vector in the Saos-2 cell line (Fig. 2). These three copies of this p53-binding site were capable of mediating a significant degree of activation in response to p53 (Fig. 2, compare 4-fold with pTATA-113/-93 to 142-fold with pTATA(-113/-93)₃), demonstrating that the sequence from -113 to -93 is indeed a bona fide p53 response element capable of both binding p53 in a sequence-specific manner *in vitro* and mediating p53-dependent transcriptional activation in cells. Confirming previous results, p53 was able to activate

-83), but this activation was significantly reduced as compared with that mediated by all three half-sites combined (Fig. 2, compare 44-fold with pTATA-102/-83 and 153-fold with pTATA-113/-83). To test the ability of half-sites one and three to mediate p53-dependent transcriptional activation, a synthetic oligonucleotide corresponding to -113 to -93 of the BAX promoter, with -102 to -93 scrambled to remove any contribution of the second half-site, was cloned into the pTATA reporter plasmid. This construct failed to be activated by p53 (Fig. 2, pTATA-113/-83(sc-102/-93)). The third half-site in isolation (-92 to -83) also failed to mediate p53-dependent transcriptional activation (Fig. 2, pTATA-92/-83).

Sp1 Binds with Sequence Specificity to and Activates Transcription through the p53 Response Element from the Human BAX Promoter—We previously reported the identification of a nuclear factor, termed Binder of BAX 1 (BoB1), that interacts with sequence specificity with the same region of the human BAX promoter that is required for p53-dependent transcriptional activation (37). These previous studies demonstrated that this factor binds to sequences within the region of -102 to -83. Analysis of this region using a MatInspector search of the TRANSFAC data base (38, 39) showed that it contains a sequence that potentially could bind the transcription factor Sp1. To test this, a synthetic oligonucleotide corresponding to -102 to -83 of the BAX promoter was used as a radiolabeled probe in an EMSA with HeLa cell nuclear extract (Fig. 3). As reported previously for Saos-2 (37), HeLa cell nuclear extract contains a factor that demonstrated marked sequence specificity for the labeled BAX probe. This factor was successfully competed by increasing amounts of unlabeled probe (Fig. 3, lanes 7-9) as well as by increasing amounts of oligonucleotide corresponding to the DNA-binding consensus sequence of Sp1 (Fig. 3, lanes 13-15). This binding was specific, as an oligonucleotide corresponding to the 5' p53 response element from the human p21 promoter failed to compete for binding (Fig. 3, lanes 10-12). In addition, this factor was successfully bound by an anti-Sp1 antibody, as demonstrated by a "supershifted" complex (Fig. 3, lanes 2 and 3), whereas a control anti-p300 antibody failed to bind the factor (Fig. 3, lanes 4 and 5). Together, these data demon-




FIG. 3. Sp1 binds with sequence specificity to the p53 response element from the human BAX promoter. An electrophoretic mobility shift assay was performed using an oligonucleotide corresponding to the -102/-83 sequence from the human BAX promoter as radiolabeled probe. 8 μ g of HeLa cell nuclear extract was incubated with 3 ng of the probe alone (lanes 1 and 6), in the presence of 2 or 4 μ l of anti-Sp1 antibody (Ab) (lanes 2 and 3, respectively), 2 or 4 μ l of anti-p300 antibody (lanes 4 and 5, respectively), a 100-, 200-, or 300-fold molar excess of either the unlabeled BAX -102/-83 oligonucleotide (lanes 7-9) or p21 5' oligonucleotide (lanes 10-12), or a 10-, 20-, or 30-fold molar excess of the unlabeled Sp1 consensus oligonucleotide (lanes 13-15). The arrows indicate the positions of the Sp1-DNA complex and the supershifted complex containing antibody, Sp1, and DNA.

strate that Sp1 can bind a portion of the p53 response element from the human BAX promoter in a sequence-specific manner.

To delineate further the sequences important for Sp1 binding, oligonucleotides were synthesized that replaced portions of the BAX sequence with corresponding sequence from the p21 5' p53 response element. The sequence from -102 to -83 in the BAX promoter contains two p53 half-sites (-102 to -93 and -92 to -83), and the p21 5' element also consists of two p53 half-sites. Hybrid oligonucleotides were synthesized in which the first of the two half-sites in the BAX element was combined with the second half-site of the p21 5' element and vice versa. The oligonucleotide corresponding to -102 to -83 of the BAX promoter again was used as a radiolabeled probe with HeLa nuclear extract in an EMSA (Fig. 4). Competitions, using unlabeled probe as well as the oligonucleotides corresponding to the p21 5' element and the two hybrid elements, were conducted. Sp1 bound the radiolabeled probe (Fig. 4, lane 1) and was recognized by an anti-Sp1 antibody (Fig. 4, lane 2) but not by a control anti-CBP antibody (Fig. 4, lane 3). Both unlabeled probe and the Sp1 DNA-binding consensus site oligonucleotide effectively competed for Sp1 binding (Fig. 4, lanes 4-5 and 12-13, respectively), whereas the p21 5' element did not (Fig. 4, lanes 10-11). Consistent with the notion that Sp1 binds DNA through GC box regions, the hybrid oligonucleotide in which the first half-site is derived from the p21 sequence and the second half-site from the BAX sequence (-92 to -83, 5'-GGGCGTGGGC-3') effectively competed for Sp1 binding (Fig. 4, lanes 8-9), whereas the other hybrid oligonucleotide that replaces this GC-rich region with sequence from the p21 5' element demonstrated a significantly reduced affinity for Sp1 binding (Fig. 4, lanes 6-7). These data indicate that Sp1 binds to sequence within -92 to -83 of the BAX promoter.

To determine whether or not Sp1 can interact with this element in cells, a pTATA luciferase reporter plasmid containing -113 to -77 of the human BAX promoter was cotransfected with increasing amounts of an Sp1 expression vector into the Sp1-deficient *Drosophila* SL2 cell line (Fig. 5). Expression of Sp1 successfully activated transcription of this reporter and yet failed to activate transcription of a control plasmid containing the 5' p53 response element of the p21 promoter (Fig. 5).




FIG. 4. The Sp1-binding site is localized to a GC-rich region of the p53 response element. A, an electrophoretic mobility shift assay was performed using an oligonucleotide corresponding to the -102/-83 sequence from the human BAX promoter as radiolabeled probe. 8 μ g of HeLa cell nuclear extract was incubated with 3 ng of the probe alone (lane 1), in the presence of 4 μ l of anti-Sp1 antibody (Ab) (lane 2), 4 μ l of anti-CBP antibody (lane 3), a 100- or 200-fold molar excess of either the unlabeled BAX -102/-83 oligonucleotide (lanes 4 and 5), p21 5' oligonucleotide (lanes 10 and 11), BAX/p21 5' hybrid oligonucleotide (lanes 6 and 7) or p21 5'/BAX hybrid oligonucleotide (lanes 8 and 9), or a 10- or 20-fold molar excess of the unlabeled Sp1 consensus oligonucleotide (lanes 12 and 13). The arrows indicate the positions of the Sp1-DNA and the supershifted antibody-Sp1-DNA complexes. B, the sequences of the human BAX promoter from -102 to -83 from the start site of transcription (gray boxes) and the human p21 promoter from -2281 to -2262 from the start site of transcription (white boxes; corresponding to the p21 5' oligonucleotide) are shown. Each sequence is divided into two with the first half indicated as A and the second half indicated as B. Oligonucleotides in A are represented graphically according to this color and letter scheme. For example, the BAX/p21 5' hybrid oligonucleotide that corresponds to the first half of the BAX sequence followed by the second half of the p21 sequence is indicated by a gray box labeled A followed by a white box labeled B.

Consistent with the *in vitro* EMSA results, this confirms that Sp1 is capable of activating transcription through the p53 response element of the human BAX promoter.

The Ability of Sp1 to Bind the p53 Response Element of the BAX Promoter in Vitro Correlates with the Ability of p53 to Activate Transcription through This Element in Cells—To explore the significance of the Sp1-binding site to the ability of p53 to activate transcription through the BAX promoter, nucleotide substitutions were identified that differentially affected the ability of p53 to activate transcription through its response element in the BAX promoter (-113 to -83). Two mutated forms of the p53 response element from the BAX promoter, in which the indicated guanine bases were replaced with adenines (Fig. 6A, GG-92/-91AA and GG-85/-84AA), were cloned into the pTATA luciferase reporter plasmid. In cotransfection assays with a wild-type p53 expression vector in




FIG. 5. Sp1 can activate transcription through the p53 response element of the human *BAX* promoter. *Drosophila* SL2 cells were transfected as described under "Experimental Procedures" with 2 μ g of the indicated pTATA reporter constructs in the presence of 0, 300, 600, or 900 ng of pPacSp1. Appropriate amounts of the vector pPacU were added to each transfection mixture to maintain a constant level of total plasmid DNA of 2.9 μ g/sample. 48 h post-transfection cells were lysed and assayed for total protein and luciferase activity as described under "Experimental Procedures." The indicated values are the average of four independent experiments expressed as the fold activation for each reporter plasmid with pPacSp1 as compared with pPacU. Error bars correspond to 1 S.D.

the Saos-2 cell line, substitution of bases -92 and -91 completely abolished the ability of p53 to activate transcription through this element (Fig. 6A, compare -113/-83 to GG-92/-91AA), whereas substitution of bases -85 and -84 did not (Fig. 6A). As observed in Figs. 1 and 2, removal of the third potential half-site (-92 to -83) inhibited the ability of p53 to mediate transcriptional activation through this element (Fig. 6A, compare -113/-83 and -113/-93), demonstrating the requirement for this Sp1-binding sequence in the p53-dependent transcriptional activation of this element.

Both of these mutant sequences were assayed for their ability to bind purified p53 in an EMSA. An oligonucleotide corresponding to -113 to -77 of the *BAX* promoter was used as a radiolabeled probe with purified p53 in an EMSA (Fig. 6B). Competitions were performed with increasing amounts of an oligonucleotide corresponding to -113 to -83 of the *BAX* promoter and the two mutant oligonucleotides. When compared with the wild-type oligonucleotide, both mutant oligonucleotides displayed a slightly decreased affinity for p53 (Fig. 6B, compare lanes 2-4 with lanes 5-7 and 8-10; Fig. 6C). Compared with one another, however, both mutant oligonucleotides demonstrated a comparable affinity for p53 (Fig. 6, A and B), suggesting that the differences in p53-dependent transcriptional activation observed in Fig. 6A are not due to differences in the affinity of p53 for the two sequences. In contrast, the abilities of the two mutant sequences to bind Sp1 differed (Fig. 6, D and E). An oligonucleotide corresponding to -113 to -77 of the *BAX* promoter was used as radiolabeled probe with extract from Sf9 cells expressing recombinant human Sp1 protein in an EMSA (Fig. 6D). Sp1 bound the probe and was recognized by an anti-Sp1 antibody (Fig. 6D, lanes 1-2). Sp1 binding was successfully competed by unlabeled BAX -113/-83 oligonucleotide as well as by the GG-85/-84AA mutated oligonucleotide (Fig. 6D, lanes 3-4 and 9-11, respectively; Fig. 6E). The GG-92/-91AA mutant, however, demonstrated a significant decrease in affinity for Sp1 (Fig. 6D, compare lanes 3-5 and 9-11 to lanes 6-8; Fig. 6E).

The results with the GG-85/-84AA mutant presented in Fig. 6 suggest that not all of the bases contained within the third potential half-site of the p53 response element are required for p53-dependent transcriptional activation. To iden-

tify the minimal sequence elements required to mediate p53-dependent transactivation, a series of oligonucleotides was synthesized in which each of the 10 bases of the third potential half-site (-92 to -83) was individually replaced. These mutant oligonucleotides then were cloned into the pTATA luciferase reporter plasmid and tested for their responsiveness to p53 in a cotransfection assay in the Saos-2 cell line (Fig. 7). Consistent with the results in Fig. 6A, substitution of the bases at either -85 or -84 did not inhibit the ability of p53 to activate transcription through this element (Fig. 7, G-85T and G-84T). Furthermore, substitution of -86 and -83 also failed to affect significantly the ability of p53 to activate transcription (Fig. 7, compare -113/-83 to G-86T and C-83A). Substitution of the base at -87, however, significantly reduced the ability of p53 to activate transcription through this element (Fig. 7, compare -113/-83 to T-87G). Together, these results suggest that the minimal response element consists of sequence from -113 to -87, with -86 to -83 being dispensable for p53-dependent transactivation.

To confirm that the bases from -86 to -83 are not required for p53-dependent transcriptional activation, two additional mutant oligonucleotides were synthesized. The first mutant was generated by replacing all 10 nucleotides from -92 to -83 (Fig. 8A, sc-92/-83). The 4 bases from -86 to -83 were substituted as indicated to generate the second mutant oligonucleotide (Fig. 8A, sc-86/-83). Each oligonucleotide was cloned into the pTATA vector and tested for its responsiveness to p53 in a cotransfection assay (Fig. 8A). As observed with the reporter plasmid in which the sequence from -92 to -83 is removed entirely (pTATA-113/-93), the first mutant, in which all 10 bases of the third potential half-site (-92 to -83) are replaced, showed little to no response to p53 (Fig. 8A, compare pTATA-113/-93 to pTATA-113/-83 and pTATAsc-92/-83). In contrast, the second mutant, in which only the last 4 bases of the element (-86 to -83) are replaced, was efficiently activated by p53 (Fig. 8A, compare 312-fold with pTATA-113/-83 to 323-fold with pTATAsc-86/-83). This result demonstrates that the minimal p53 response element in the *BAX* promoter consists of sequence from -113 to -87. In an EMSA both mutants displayed a decreased affinity for p53 as compared with the wild-type sequence (Fig. 8B, compare lanes 2-4 to lanes 8-10 and 11-13; Fig. 8C). When compared with each other, there was no significant difference in the affinity of p53 for the two mutant sequences (Fig. 8B, compare lanes 8-10 to 11-13; Fig. 8C). This suggests that the differences in transcriptional activation observed in Fig. 8A cannot be explained by differences in p53 affinities. Furthermore, the oligonucleotide corresponding to -113 to -93 displayed a similar affinity for p53 as the two mutant oligonucleotides (Fig. 8B, compare lanes 5-7 to lanes 8-10 and 11-13; Fig. 8C) consistent with the idea that, in the case of the two mutants, p53 is interacting with the first and the second half-sites only. The sc -86/-83 mutant oligonucleotide efficiently competed for Sp1 binding in an EMSA (Fig. 8D, compare lanes 2-4 to lanes 8-10; Fig. 8E), whereas the ability of the sc -92/-83 mutant to bind Sp1 was significantly reduced compared with the wild-type sequence (Fig. 8D, compare lanes 2-4 to lanes 5-7; Fig. 8E), further strengthening the correlation between Sp1 binding *in vitro* and p53 activation in cells.

DISCUSSION

The data presented in this report demonstrate that the minimum p53 response element in the *BAX* promoter consists of the sequence from -113 to -87 from the start site of transcription. This sequence contains a p53-binding site (-113 to -93) that can function as a *bona fide* response element as demonstrated by its ability when multimerized to confer p53-depend-





FIG. 6. A mutant element that fails to bind Sp1 *in vitro* also fails to confer p53-dependent transcriptional activation in cells. **A**, Saos-2 cells were transfected as described under "Experimental Procedures" with 1 μ g of the indicated pTATA reporter constructs in the presence of either 10 ng of pCMV (white bars) or 10 ng of pCMV-p53^{wt} (gray bars). 24 h post-transfection cells were lysed and assayed for total protein and luciferase activity as described under "Experimental Procedures." The indicated values are the average of five independent experiments each performed in duplicate. Error bars correspond to 1 S.D. The GC-rich region that binds Sp1 is shown by the boxed sequence. Bases in the wild-type sequence that were mutated are shown in gray with the corresponding mutations indicated above. **B**, an electrophoretic mobility shift assay was performed using an oligonucleotide corresponding to the -113/-77 sequence from the human *BAX* promoter as radiolabeled probe. 50 ng of purified p53 was incubated with 3 ng of the probe alone (lane 1) or in the presence of a 500-, 1000-, or 1500-fold molar excess of either the unlabeled BAX -113/-83 oligonucleotide (lanes 2-4), the GG-92/-91AA oligonucleotide (lanes 5-7), or the GG-85/-84AA oligonucleotide (lanes 8-10). The arrow indicates the position of the p53-DNA complex. The vertical bar between lanes 4 and 5 represents the removal of irrelevant lanes from the gel. **C**, bands were quantitated by densitometry. **D**, an electrophoretic mobility shift assay was performed using an oligonucleotide corresponding to the -113/-77 sequence from the human *BAX* promoter as radiolabeled probe. Extract from Sf9 cells expressing human recombinant Sp1 protein was incubated with 3 ng of the probe alone (lane 1), in the presence of anti-Sp1 antibody (lane 1), or in the presence of a 50-, 100-, or 200-fold molar excess of either the unlabeled BAX -113/-83 oligonucleotide (lanes 3-5), the GG-92/-91AA oligonucleotide (lanes 6-8), or the GG-85/-84AA oligonucleotide (lanes 9-11). The arrow indicates the position of the Sp1-DNA complex, and the asterisk indicates the position of the supershifted anti-Sp1-DNA complex. The vertical bar between lanes 5 and 6 represents the removal of irrelevant lanes from the gel. **E**, bands were quantitated by densitometry.

ent transcriptional activation on a minimal promoter (Fig. 2). Immediately adjacent to this p53-binding site are 6 base pairs that are GC-rich in nature (-92 to -87: 5'-GGGCGT-3'). These 6 bases are required for p53-dependent transcriptional activation as deletion or mutation of this region in the context of either the promoter or the isolated response element completely abrogates the ability of p53 to activate transcription through this sequence (Figs. 1B, 2, 6A, and 8A). The addition of these bases to the -113/-93 sequence appears to have little effect on the affinity of p53 for this sequence (Fig. 8, B and C), consistent with a model in which these 6 bases function to

recruit a co-activator as opposed to simply enhancing p53 binding. Furthermore, these 6 base pairs mediate sequence-specific binding to the Sp1 transcription factor (Figs. 3, 4, 6D, and 8D), and a positive correlation is seen between the ability of Sp1 to bind this element *in vitro* and the ability of p53 to mediate transcriptional activation through its response element in cells (Figs. 6 and 8). In addition, the results with electrophoretic mobility shift assays with the GG-92/-91AA mutant oligonucleotide (Fig. 6B) are not consistent with the published p53 DNA-binding consensus sequence of (RRRCWWGYYY)₂ (18, 19). This consensus allows for a purine in the first three posi-

FIG. 7. Mutational analysis shows that the BAX promoter sequence from -86 to -83 is not required for p53-dependent transcriptional activation. Saos-2 cells were transfected as described under "Experimental Procedures" with 1 μ g of the indicated pTATA reporter constructs in the presence of either 10 ng of pCMV (white bars) or 10 ng of pCMV-p53^{wt} (gray bars). 24 h post-transfection cells were lysed and assayed for total protein and luciferase activity as described under "Experimental Procedures." The indicated values are the average of three independent experiments each performed in duplicate. Error bars correspond to 1 S.D. The GC-rich region that binds Sp1 is shown by the boxed sequence. Bases in the wild-type sequence that were mutated are shown in gray with the corresponding mutations indicated above.



tions of each half-site. The GG-92/-91AA mutant contains a conservative substitution of purines (adenines) for purines (guanines) and, as such, does not represent a substantive change in terms of the p53 DNA-binding consensus sequence. This substitution, however, did produce a significant decrease in the ability of p53 to bind to this oligonucleotide *in vitro* (Fig. 6B), suggesting that, in these limited circumstances, the p53 DNA-binding sequence involves greater specificity than implied by the consensus.

Previous studies have suggested a connection between p53 and Sp1. The two proteins physically interact under certain circumstances (40-42), and, transcriptionally, p53 and Sp1 have been shown to function in a cooperative manner in some settings and an antagonistic manner in others (41, 43, 44). In addition to p53, Sp1 has been found to synergize with other transcription factors, including YY1 and SREBP (45-47). Studies with the Sp family of transcription factors, however, are complicated by the fact that there are at least 16 mammalian members of this family. Due to marked conservation in the DNA-binding domain, many of these family members have similar if not identical *in vitro* DNA binding characteristics (48, 49). Originally, this led to the misclassification of many GC boxes solely as Sp1-binding sites because of the ubiquitous nature of Sp1 and the fact that it was the first family member cloned. Given this, the possibility exists that the true *in vivo* cofactor required for the p53-dependent transactivation of the BAX promoter is an Sp1-related family member that is ob-

scured in *in vitro* assays by the sheer abundance of Sp1 in nuclear extracts from tissue culture cells. Consistent with this, antibodies used in a supershift EMSA identified other Sp family members as minor components of the Sp1-DNA complex.² Furthermore, cotransfection assays in the Sp1-deficient *Drosophila* SL2 cell line failed to demonstrate cooperation between Sp1 and p53 in transcriptionally activating the p53 response element of the BAX promoter.² The *Drosophila* assays, however, are difficult to interpret as the ability of p53 alone to activate transcription through a control plasmid was significantly impaired in the SL2 cell line. Complicating interpretation of the results in the *Drosophila* system is the recent identification of a *Drosophila* p53 homolog (50, 51) that may affect the ability of transiently expressed human p53 to function properly in this system.

Regardless of whether the cofactor required for the p53-dependent transactivation of the BAX promoter is Sp1 or a related family member, the requirement of this cooperating protein suggests a model for the observed cell type- and tumor type-specific regulation of the BAX gene by wild-type p53 (Fig. 9). In this model, cells that are permissive to p53-dependent up-regulation of the BAX gene express both p53 and the cofactor, and these proteins function together to activate transcriptionally the gene. In those cells that fail to show p53-dependent

² E. C. Thornborrow and J. J. Manfredi, unpublished data.




FIG. 9. Model for the cell type-specific regulation of the BAX promoter by the tumor suppressor protein p53. A, in cells that are permissive to p53-dependent transcriptional activation of the BAX gene, p53 and the required cofactor cooperate to mediate activation. In cells that do not support the p53-BAX pathway, three possible mechanisms may explain the apparent failure of wild-type p53 to activate the BAX gene. B, the cofactor may be absent due to mutation or to cell type-specific limitations on its expression. C, the cofactor may be inactivated by post-translational modification as follows: P, phosphorylation; G, glycosylation; or A, acetylation. D, another factor that cannot cooperate with p53 may compete with the required cofactor for binding to its site in the BAX promoter. The p53-binding site (–113 to –93) is represented by the black box. The Sp1-binding site (–93 to –87) is represented by the white box. p53, the required cofactor, and the inhibitory factor are represented by the gray circle, the dotted oval, and the cross-hatched triangle, respectively.

case, transcriptional activation by one family member is repressed by the other member by competing for the same DNA-binding site. The data in this report, in combination with the previous studies of the Sp family of transcription factors, support a model in which the regulation of a required cofactor controls cell type-specific p53-dependent expression of the BAX gene.

The ability of the proapoptotic BAX to function as a tumor suppressor protein has been substantiated by several studies. In certain mouse models, BAX has been shown to be an important mediator of p53-dependent apoptosis and a suppressor of oncogenic transformation, with loss of BAX leading to accelerated rates of tumor growth, increased tumor numbers, larger tumor mass, and decreased survival rates (63, 64). A significant correlation between decreased BAX expression and both a corresponding resistance to apoptotic stimuli, as well as a shorter survival period also have been observed in a number of human tumor types, including breast, ovarian, pancreatic, colorectal, and non-Hodgkin's lymphoma (65–69). In addition, in colon and gastric cancers of the microsatellite mutator phenotype mutational inactivation of the BAX gene has been shown to confer a strong survival advantage during tumor clonal evolution (70). Complimenting these data are observations showing that overexpression of the BAX protein in certain tumor cell lines both sensitizes these cells to chemotherapy- and radiation-induced apoptosis and reduces their ability to form tumors in SCID mice (71–73). Together, these results strongly support a tumor suppressor role for the BAX protein.

An important regulator of the BAX gene is the tumor suppressor protein p53. Several reports have demonstrated the significance of the p53-BAX pathway in tumor suppression. Both the identification of tumor-derived p53 mutants that selectively fail to activate transcription through the BAX promoter and subsequently fail to induce apoptosis (29–32) as well as the TgT121 transgenic studies that demonstrate that BAX is an obligatory downstream effector of p53 in the suppression of choroid plexus tumor growth (33) suggest that the ability of p53 to activate transcription through the BAX promoter is important to the tumor suppressor function of p53. Furthermore, the resistance of certain tumor cell lines to radiation therapy is associated with a failure of wild-type p53 to induce BAX expression (28, 74), and certain human tumors have been identified that are genetically wild-type for both p53 and BAX and yet fail to express significant levels of BAX protein (75). Thus, a complete understanding of the transcriptional regulation of the BAX gene by the tumor suppressor p53 may provide important information concerning both the molecular origins of

cancer as well as the development of tumor resistance to certain cancer treatments.

Acknowledgments—We thank Bert Vogelstein (The Johns Hopkins University) for the wild-type p53 expression plasmid; John Reed (Burnham Institute) for the original pBAX reporter construct; Robert Tjian and Andres Naar (University of California at Berkeley) for the pPacSp1 expression plasmid and the recombinant baculovirus expressing human Sp1; and Ze'ev Ronai (Mount Sinai) for the recombinant baculovirus expressing His-tagged human p53. We thank Ron Magnusson for help with the recombinant baculovirus infections. We also thank Lois Resnick-Silverman of the Manfredi laboratory for help and support. The technical assistance of Andrea DaCosta is gratefully acknowledged.

REFERENCES

- Jurgensmeier, J. M., Xie, Z., Deveraux, Q., Ellerby, L., Bredesen, D., and Reed, J. C. (1998) *Proc. Natl. Acad. Sci. U. S. A.* **95**, 4997–5002
- Manon, S., Chaudhuri, B., and Guerin, M. (1997) *FEBS Lett.* **415**, 29–32
- Pastorino, J. G., Chen, S. T., Tafani, M., Snyder, J. W., and Farber, J. L. (1998) *J. Biol. Chem.* **273**, 7770–7775
- Skulachev, V. P. (1998) *FEBS Lett.* **423**, 275–280
- Kim, C. N., Wang, X., Huang, Y., Ibrado, A. M., Liu, L., Fang, G., and Bhalla, K. (1997) *Cancer Res.* **57**, 3115–3120
- Oltvai, Z. N., Millman, C. L., and Korsmeyer, S. J. (1993) *Cell* **74**, 609–619
- Miyashita, T., Krajewski, S., Krajewska, M., Wang, H. G., Lin, H. K., Liebermann, D. A., Hoffman, B., and Reed, J. C. (1994) *Oncogene* **9**, 1799–1805
- Miyashita, T., and Reed, J. C. (1995) *Cell* **80**, 293–299
- Ko, L. J., and Prives, C. (1996) *Genes Dev.* **10**, 1054–1072
- Levine, A. J. (1997) *Cell* **88**, 323–331
- Bargonetti, J., Friedman, P. N., Kern, S. E., Vogelstein, B., and Prives, C. (1991) *Cell* **65**, 1083–1091
- Kern, S. E., Kinzler, K. W., Bruskin, A., Jarosz, D., Friedman, P., Prives, C., and Vogelstein, B. (1991) *Science* **252**, 1708–1711
- Fields, S., and Jang, S. K. (1990) *Science* **249**, 1046–1049
- Bargonetti, J., Manfredi, J. J., Chen, X., Marshak, D. R., and Prives, C. (1993) *Genes Dev.* **7**, 2565–2574
- Pavletich, N. P., Chambers, K. A., and Pabo, C. O. (1993) *Genes Dev.* **7**, 2556–2564
- Wang, Y., Reed, M., Wang, P., Stenger, J. E., Mayr, G., Anderson, M. E., Schwedes, J. F., and Tegtmeyer, P. (1993) *Genes Dev.* **7**, 2575–2586
- Pietenpol, J. A., Tokino, T., Thiagalingam, S., el-Deiry, W. S., Kinzler, K. W., and Vogelstein, B. (1994) *Proc. Natl. Acad. Sci. U. S. A.* **91**, 1998–2002
- el-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., and Vogelstein, B. (1992) *Nat. Genet.* **1**, 45–49
- Funk, W. D., Pak, D. T., Karas, R. H., Wright, W. E., and Shay, J. W. (1992) *Mol. Cell. Biol.* **12**, 2866–2871
- Buckbinder, L., Talbot, R., Velasco-Miguel, S., Takenaka, I., Faha, B., Seizinger, B. R., and Kley, N. (1995) *Nature* **377**, 646–649
- el-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. (1993) *Cell* **75**, 817–825
- el-Deiry, W. S., Tokino, T., Waldman, T., Oliner, J. D., Velculescu, V. E., Burrell, M., Hill, D. E., Healy, E., Rees, J. L., and Hamilton, S. R. (1995) *Cancer Res.* **55**, 2910–2919
- Hollander, M. C., Alamo, I., Jackman, J., Wang, M. G., McBride, O. W., and Fornace, A. J., Jr. (1993) *J. Biol. Chem.* **268**, 24385–24393
- Macleod, K. F., Sherry, N., Hannon, G., Beach, D., Tokino, T., Kinzler, K., Vogelstein, B., and Jacks, T. (1995) *Genes Dev.* **9**, 935–944
- Perry, M. E., Piette, J., Zawadzki, J. A., Harvey, D., and Levine, A. J. (1993) *Proc. Natl. Acad. Sci. U. S. A.* **90**, 11623–11627
- Zauberman, A., Lupo, A., and Oren, M. (1995) *Oncogene* **10**, 2361–2366
- Bouvard, V., Zaitchouk, T., Vacher, M., Duthu, A., Canivet, M., Choisy-Rossi, C., Nieruchalski, M., and May, E. (2000) *Oncogene* **19**, 649–660
- Zhan, Q., Fan, S., Bae, I., Guillof, C., Liebermann, D. A., O'Connor, P. M., and Fornace, A. J., Jr. (1994) *Oncogene* **9**, 3743–3751
- Di Como, C. J., and Prives, C. (1998) *Oncogene* **16**, 2527–2539
- Flaman, J. M., Robert, V., Lenglet, S., Moreau, V., Iggo, R., and Frebourg, T. (1998) *Oncogene* **16**, 1369–1372
- Friedlander, P., Haupt, Y., Prives, C., and Oren, M. (1996) *Mol. Cell. Biol.* **16**, 4961–4971
- Ludwig, R. L., Bates, S., and Voudsen, K. H. (1996) *Mol. Cell. Biol.* **16**, 4952–4960
- Yin, C., Knudson, C. M., Korsmeyer, S. J., and Van Dyke, T. (1997) *Nature* **385**, 637–640
- Resnick-Silverman, L., St. Clair, S., Maurer, M., Zhao, K., and Manfredi, J. J. (1998) *Genes Dev.* **12**, 2102–2107
- Baker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K., and Vogelstein, B. (1990) *Science* **249**, 912–915
- Courey, A. J., and Tjian, R. (1988) *Cell* **55**, 887–898
- Thornbrough, E. C., and Manfredi, J. J. (1999) *J. Biol. Chem.* **274**, 33747–33756
- Quandt, K., Frech, K., Karas, H., Wingender, E., and Werner, T. (1995) *Nucleic Acids Res.* **23**, 4878–4884
- Wingender, E., Chen, X., Hehl, R., Karas, H., Liebig, I., Matys, V., Meinhardt, T., Pruss, M., Reuter, I., and Schacherer, F. (2000) *Nucleic Acids Res.* **28**, 316–319
- Borellini, F., and Glazer, R. I. (1993) *J. Biol. Chem.* **268**, 7923–7928
- Gualberto, A., and Baldwin, A. S., Jr. (1995) *J. Biol. Chem.* **270**, 19680–19683
- Ohlsson, C., Kley, N., Werner, H., and LeRoith, D. (1998) *Endocrinology* **139**, 1101–1107

43. Bargonetti, J., Chicas, A., White, D., and Prives, C. (1997) *Cell Mol. Biol. (Noisy-le-Grand)* **43**, 935-949
44. Wang, Q., and Beck, W. T. (1998) *Cancer Res.* **58**, 5762-5769
45. Athanikar, J. N., Sanchez, H. B., and Osborne, T. F. (1997) *Mol. Cell. Biol.* **17**, 5193-5200
46. Sanchez, H. B., Yieh, L., and Osborne, T. F. (1995) *J. Biol. Chem.* **270**, 1161-1169
47. Seto, E., Lewis, B., and Shenk, T. (1993) *Nature* **365**, 462-464
48. Philipsen, S., and Suske, G. (1999) *Nucleic Acids Res.* **27**, 2991-3000
49. Suske, G. (1999) *Gene (Amst)* **238**, 291-300
50. Jin, S., Martinek, S., Joo, W. S., Wortman, J. R., Mirkovic, N., Sali, A., Yandell, M. D., Pavletich, N. P., Young, M. W., and Levine, A. J. (2000) *Proc. Natl. Acad. Sci. U. S. A.* **97**, 7301-7306
51. Ollmann, M., Young, L. M., Di Como, C. J., Karim, F., Belvin, M., Robertson, S., Whittaker, K., Demsky, M., Fisher, W. W., Buchman, A., Duyk, G., Friedman, L., Prives, C., and Kopczynski, C. (2000) *Cell* **101**, 91-101
52. Apt, D., Watts, R. M., Suske, G., and Bernard, H. U. (1996) *Virology* **224**, 281-291
53. Discher, D. J., Bishopric, N. H., Wu, X., Peterson, C. A., and Webster, K. A. (1998) *J. Biol. Chem.* **273**, 26087-26093
54. Shields, J. M., Christy, R. J., and Yang, V. W. (1996) *J. Biol. Chem.* **271**, 20009-20017
55. Ye, J., Xu, R. H., Taylor-Papadimitriou, J., and Pitha, P. M. (1996) *Mol. Cell. Biol.* **16**, 6178-6189
56. Saffer, J. D., Jackson, S. P., and Annarella, M. B. (1991) *Mol. Cell. Biol.* **11**, 2189-2199
57. Jackson, S. P., and Tjian, R. (1988) *Cell* **55**, 125-133
58. Jackson, S. P., MacDonald, J. J., Lees-Miller, S., and Tjian, R. (1990) *Cell* **63**, 155-165
59. Zhang, W., and Bieker, J. J. (1998) *Proc. Natl. Acad. Sci. U. S. A.* **95**, 9855-9860
60. Hagen, G., Muller, S., Beato, M., and Suske, G. (1994) *EMBO J.* **13**, 3843-3851
61. Imhof, A., Schuierer, M., Werner, O., Moser, M., Roth, C., Bauer, R., and Buettner, R. (1999) *Mol. Cell. Biol.* **19**, 194-204
62. Turner, J., and Crossley, M. (1999) *Int. J. Biochem. Cell Biol.* **31**, 1169-1174
63. McCurrach, M. E., Connor, T. M., Knudson, C. M., Korsmeyer, S. J., and Lowe, S. W. (1997) *Proc. Natl. Acad. Sci. U. S. A.* **94**, 2345-2349
64. Shibata, M. A., Liu, M. L., Knudson, M. C., Shibata, E., Yoshidome, K., Bandey, T., Korsmeyer, S. J., and Green, J. E. (1999) *EMBO J.* **18**, 2692-701
65. Bargou, R. C., Daniel, P. T., Mapara, M. Y., Bommert, K., Wagener, C., Kallinich, B., Royer, H. D., and Dorken, B. (1995) *Int. J. Cancer* **60**, 854-859
66. Friess, H., Lu, Z., Graber, H. U., Zimmermann, A., Adler, G., Korc, M., Schmid, R. M., and Buchler, M. W. (1998) *Gut* **43**, 414-421
67. Gascoyne, R. D., Krajewska, M., Krajewski, S., Connors, J. M., and Reed, J. C. (1997) *Blood* **90**, 3173-3178
68. Krajewski, S., Blomqvist, C., Franssila, K., Krajewska, M., Wasenius, V. M., Niskanen, E., Nordling, S., and Reed, J. C. (1995) *Cancer Res.* **55**, 4471-4478
69. Sturm, I., Kohne, C. H., Wolff, G., Petrowsky, H., Hillebrand, T., Hauptmann, S., Lorenz, M., Dorken, B., and Daniel, P. T. (1999) *J. Clin. Oncol.* **17**, 1364-1374
70. Ionov, Y., Yamamoto, H., Krajewski, S., Reed, J. C., and Peruchio, M. (2000) *Proc. Natl. Acad. Sci. U. S. A.* **97**, 10872-10877
71. Bargou, R. C., Wagener, C., Bommert, K., Mapara, M. Y., Daniel, P. T., Arnold, W., Dietel, M., Guski, H., Feller, A., Royer, H. D., and Dorken, B. (1996) *J. Clin. Invest.* **97**, 2651-2659
72. Sakakura, C., Sweeney, E. A., Shirahama, T., Igarashi, Y., Hakomori, S., Nakatani, H., Tsujimoto, H., Imanishi, T., Ohgaki, M., Ohyama, T., Yamazaki, J., Hagiwara, A., Yamaguchi, T., Sawai, K., and Takahashi, T. (1996) *Int. J. Cancer* **67**, 101-105
73. Wagener, C., Bargou, R. C., Daniel, P. T., Bommert, K., Mapara, M. Y., Royer, H. D., and Dorken, B. (1996) *Int. J. Cancer* **67**, 138-141
74. Shu, H. K., Kim, M. M., Chen, P., Furman, F., Julin, C. M., and Israel, M. A. (1998) *Proc. Natl. Acad. Sci. U. S. A.* **95**, 14453-14458
75. Sturm, I., Papadopoulos, S., Hillebrand, T., Benter, T., Luck, H. J., Wolff, G., Dorken, B., and Daniel, P. T. (2000) *Int. J. Cancer* **87**, 517-521

A conserved intronic response element mediates direct p53-dependent transcriptional activation of both the human and murine *bax* genes

Edward C. Thornborrow, Elissa M. Schwartzfarb, and James J. Manfredi*

The Derald H. Ruttenberg Cancer Center, Mount Sinai School of Medicine, New York, New York 10029

Running title: p53-dependent transactivation of *bax*

Keywords: p53, *bax*, transcription, DNA binding

***Corresponding author.** Mailing address: Derald H. Ruttenberg Cancer Center, Box 1130, Mount Sinai School of Medicine, New York, NY 10029. Phone: (212) 659-5495. Fax: (212) 849-2446. Email: james.manfredi@mssm.edu.

GenBank Accession #s: AF339054 and AF339055.

Abstract

Recent studies demonstrating that both the human and mouse *bax* promoters fail to respond to p53 have brought into question whether *bax* is a direct target of p53. Here, data are presented identifying an evolutionarily conserved p53 response element in the first intron of both the human and the murine *bax* genes. Electrophoretic mobility shift assays demonstrated that this sequence is capable of mediating sequence-specific binding to p53, and transfection assays showed that this element is both required and sufficient to mediate p53 dependent transcriptional activation of the *bax* gene from both species. These results demonstrate that *bax* is a direct and evolutionarily conserved transcriptional target of p53.

Introduction

Bax is an important mediator of apoptosis. Miyashita and Reed identified the human *bax* gene as a transcriptional target of p53 (1,2). Supporting this notion, a p53 response element in the promoter of the human *bax* gene has been demonstrated at -113 to -83 from the start site of transcription (2,3). The recent cloning of the murine *bax* promoter, however, has questioned the significance of this response element. Two independent reports have demonstrated that the murine *bax* promoter is unresponsive to p53 (4,5), suggesting a lack of evolutionary conservation with respect to the ability of p53 to transcriptionally regulate *bax* expression. To assay for additional sequence elements that influence p53-dependent transcriptional activation, extended pieces of both the human and murine *bax* genes were cloned. Here is presented data

demonstrating that both the human and murine *bax* genes are direct transcriptional targets of the tumor suppressor protein p53. Sequence analysis of these two genes identified two regions conserved between human and mouse. The first region corresponds to the previously characterized p53 response element in the human *bax* promoter at -113 to -83 from the start site of transcription. The second region of conservation is found in the first intron of both genes and resembles the p53 DNA-binding consensus sequence. Both regions in the human and murine *bax* genes are capable of binding p53 in a sequence specific manner *in vitro* and of conferring p53 responsiveness upon a minimal promoter in cells. Further, it is demonstrated that the p53 response element in the first intron of the human and murine *bax* genes is both required and sufficient for p53-dependent transcriptional activation.

Materials and Methods

Oligonucleotides and plasmids

With respect to the human *bax* gene, numbering is in reference to the start of transcription, while in the mouse gene numbering is from the start of translation. The following double-stranded oligonucleotides were used in electrophoretic mobility shift assays, and were cloned into pTATA (6) to produce vectors with corresponding names:

HuBax-113/-83, AATTCGGTACCTCACAAAGTTAGAGACAAGCCTGGGCGTGGGCGCTAGCGAATT;

HuBax+657/+676, AATTCGGTACCGGGCAGGCCCGGGCTTGTCGGCTAGCGAATT;

MuBax-341/-302,

AATTCGGTACCGATGACAAGCATATCCCAGGCAAGCTTTGAACTTGCGGCAGCTAGCGAATT;

MuBax-341/-315, AATTCGGTACCGATGACAAGCATATCCCAGGCAAGCTTGCTAGCGAATT;

MuBax-324/-315, AATTCGGTACCAGGCAAGCTTTGAACTTGCGGCAGCTAGCGAATT;

Bak, AATTCGCTAGCGGGCCAGGCCAGGAGCATGTCCCGCCCACTTTCCCGGTACCGAATT;

Sens-1, AATTCGGTACCTCGAAGAAGACGTGCAGGGACCCGCTAGCGAATT.

Hu+408/+989 was generated by the PCR amplification of intron 1 (+408 to +989) of the *bax* gene from human genomic DNA, and subsequent cloning of this product into pTATA. The region in Hu+408/+989 corresponding to +657 to +676 was replaced with the NcoI restriction site to produce Hu+408/+989 Δ In. Mu+1/+541 was generated by the PCR amplification of +1 to +541 of the *bax* gene from murine genomic DNA, and subsequent cloning of this product into pTATA. The region in Mu+1/+541 corresponding to +183 to +202 was replaced with the SacI restriction site to produce Mu+1/+541 Δ In. HuBax was generated by PCR amplification of -571 to +1028 of the *bax* gene from human genomic DNA, and cloning of this product into the pGL3-Basic reporter plasmid. HuBax Δ Pr and HuBax Δ In were derived from HuBax by replacing the relevant sequences, -113 to -84 and +652 to +676 respectively, with the BglII restriction site. MuBax was generated by PCR amplification of -898 to +542 of the *bax* gene from mouse genomic DNA, and cloning of this PCR product into pGL3-Basic. MuBax Δ Pr and MuBax Δ In were derived from MuBax by replacing the relevant sequences, -339 to -304 and +183 to +202 respectively, with the BglII restriction site. The expression plasmids, pCMV-p53^{wt} and p11-4mup53^{wt}, previously have been described (7,8).

Transfections

2×10^5 Saos-2 cells were transfected using Lipofectamine Plus Reagent (GibcoBRL, Life Technologies). Total protein concentration and luciferase assays were quantitated 24 h post transfection.

Electrophoretic Mobility Shift Assay

Production of baculovirus-infected Sf9 cell extracts, purification of recombinant human p53 protein, and electrophoretic mobility shift assays were conducted as previously described (6).

Results

Cloning of the human and murine bax genes identifies a putative p53 response element in the first intron.

To identify sequence elements that participate in p53-dependent transcriptional activation of the human *bax* gene, a 1599 bp fragment (-571/+1028 from the start site of transcription) of this gene was PCR cloned from human genomic DNA (Figure 1A, Accession #AF339054). This sequence contains the previously identified p53 response element at -113/-83 (Figure 1A, upper box). Sequence analysis of the first intron revealed 20 bp at +657/+676 that matched the p53 DNA-binding consensus sequence at 18 of 20 bases (Figure 1A, lower box, mismatches indicated by asterisks). This sequence was confirmed in three independent PCRs of human

genomic DNA, and, subsequently, has been confirmed independently by the Human Genome Project (Accession #11425312).

To assess whether or not the two p53 response elements observed in the human *bax* gene are evolutionarily conserved, a 1440 bp fragment (-898 to +542 from the start site of translation) of the murine *bax* gene was PCR cloned from mouse genomic DNA (Figure 1B, Accession #AF339055). Sequence analysis of the murine gene identified partial conservation of the promoter response element at -339/-304 (Figure 1B, upper sequence, solid lines represent identities, dashed lines represent conservative substitutions). As with the human sequence, if one applies the p53 DNA-binding consensus sequence of 5'-RRRCWWGYYY-3' to this region three potential p53 half-sites are identified (Figure 1B, upper boxes labeled 1-3). Of note is the Cytosine (C) at position -332 (Figure 1B, arrow). This base is consistent with the murine *bax* promoter sequence published by Schmidt *et al.* (5), but is not found in the sequence published by Igata *et al.* (4) nor is it found in their accompanying GenBank submission (Accession #AB029557). To confirm the presence of this base, this region was PCR cloned from mouse genomic DNA and sequenced on five independent occasions. In each case the C was present at position -332.

An additional region of conservation between the mouse and human *bax* genes was identified in the first intron. This 43 bp region at +177/+219 in the murine *bax* gene was found to be 93% identical to the human *bax* sequence at +651/+693 (Figure 1B, lower sequence, solid lines represent identities, dashed lines represent conservative substitutions). Further, the putative

p53 response element at +657/+676 in the human *bax* gene is perfectly conserved in the mouse intron at +183/+202 (Figure 3, lower boxes). As with the promoter region, the sequence of the murine *bax* intron was confirmed by five independent PCRs.

p53 requires the intronic response element to mediate transcriptional activation of the human bax gene.

To determine whether the sequence from +657/+676 in the human *bax* gene constitutes a *bona fide* p53 response element, a synthetic oligonucleotide corresponding to this sequence was used as a radiolabeled probe in an Electrophoretic Mobility Shift Assay (EMSA) with purified p53 (Figure 1C). Purified p53 bound the labeled oligonucleotide containing the putative response element (Figure 1C, lane 1), and this binding was effectively competed by an excess of the same, unlabeled oligonucleotide (Figure 1C, lanes 5-7). An oligonucleotide corresponding to the p53 response element at -113/-83 also competed for p53 binding (Figure 1C, lanes 2-4). An unrelated control oligonucleotide, Sens-1, was unable to compete for p53 binding (Figure 1C, lanes 8-10), demonstrating that the binding of p53 to +657/+676 is sequence-specific.

To determine the significance of this 20 bp element to p53-dependent activation in cells, luciferase reporter plasmids containing different regions of the human *bax* gene were constructed (Figure 2A) and cotransfected with either pCMV or a wild-type p53 expression vector into the p53-negative osteosarcoma Saos-2 cell line (Figure 2). When cloned upstream of a minimal promoter, the first intron of the human *bax* gene (Figure 2A, Hu+408/+989) mediated a

significant degree of activation in response to p53 (Figure 2B, Hu+408/+989). Deletion of the putative p53 response element at +657/+676 (Figure 2A, Hu+408/+989 Δ In) abolished the ability of p53 to transcriptionally activate (Figure 2B, Hu+408/+989 Δ In), demonstrating that the first intron of the human *bax* gene can confer p53 responsiveness upon a minimal promoter and that the p53 response element at +657/+676 is required for this activity. To determine if this 20 bp element is sufficient to mediate p53-dependent transcriptional activation, an oligonucleotide corresponding to this sequence was cloned into the reporter (Figure 2A, HuBax+657/+676). When cotransfected with a wild-type p53 expression vector, this reporter plasmid mediated a significant degree of activation in response to p53 (Figure 2C, HuBax+657/+676). Thus, the 20 bp from +657/+676 is sufficient to confer p53-dependent transcriptional activation upon a minimal promoter. A reporter with no insert as well as a reporter containing an unrelated sequence from the human *bak* promoter failed to respond to wild-type p53 (Figure 2C, Empty and Bak).

To address the significance of this intronic p53 response element in the larger context of the human *bax* gene, a reporter plasmid was made in which the *bax* gene from -571 to +1028 was cloned in frame with luciferase (Figure 2A, HuBax). When transfected into Saos-2 cells, this reporter plasmid mediated a significant degree of transcriptional activity in response to a cotransfected p53 expression vector (Figure 2D, HuBax). There was no substantial difference between the p53 responsiveness of this reporter as compared to a reporter in which the previously characterized p53 response element at -113/-83 is deleted (Figure 2A,

HuBax Δ Pr)(Figure 2D, compare 3.5-3.8 fold with HuBax to 2.8-3.3 fold with HuBax Δ Pr). Deletion of the intronic region containing the newly identified p53 response element (Figure 2A, HuBax Δ In), however, produced a reporter that was unresponsive to wild-type p53 (Figure 2D, HuBax Δ In), demonstrating that this element is required for p53 to mediate transcriptional activation of the human *bax* gene.

Both p53 response elements are functionally conserved in the murine bax gene.

To determine if there is functional conservation of the promoter response element, synthetic oligonucleotides corresponding to -113/-83 in the human *bax* gene and to -341/-302 in the murine *bax* gene were cloned upstream of a minimal promoter and cotransfected into cells with either an expression vector for human or murine wild-type p53 (Figure 3A). Both human and murine p53 effectively activated transcription through the p53 response element from the human *bax* promoter (Figure 3A, HuBax-113/-83, white and black bars respectively). Human and murine p53 also activated transcription through the murine *bax* sequence (Figure 3A, MuBax-342/-302, white and black bars respectively). The level of activation observed with the murine element, however, was significantly reduced as compared to that seen with the human sequence (Figure 3A, compare 98-fold and 95-fold with HuBax-113/-83 to 19-fold and 7-fold with MuBax-341/-302). Again, the reporter containing an unrelated sequence from the human *bak* promoter did not respond to p53 (Figure 3A, Bak).

To confirm that p53 is capable of binding the murine sequence from -341/-302, oligonucleotides corresponding to either this sequence (Figure 3B, upper panel) or the human sequence from -113/-83 (Figure 3B, lower panel) were used as radiolabeled probes in EMSAs. Purified p53 bound both radiolabeled probes (Figure 3B, lane 1), and was effectively competed by increasing amounts of unlabeled human and murine *bax* oligonucleotides (Figure 3B, lanes 2-4 and 5-7 respectively). An unrelated oligonucleotide, Sens-1, failed to compete for p53 binding with either probe (Figure 3B, lanes 8-10), demonstrating that the binding of p53 to both the human and murine *bax* promoter elements is specific.

The p53 response element from the human *bax* promoter has been shown to require sequence from three adjacent half-sites to effectively mediate p53-dependent transcriptional activation (3). To determine if this requirement for three half-sites is conserved in the murine response element, oligonucleotides corresponding to the first and second half-sites and the second and third half-sites were cloned into the pTATA luciferase reporter vector and assayed for their ability to confer p53 responsiveness upon a minimal promoter in cells (Figure 3C). As seen in Figure 4A, the murine sequence from -341/-302, containing all three potential p53 half-sites, was activated in response to p53 (Figure 3C, MuBax-341/-302). Similar to results observed with the p53 response element from the human *bax* promoter (3), neither the combination of the first and second nor the second and third half-sites was sufficient to mediate activation in response to p53 (Figure 3C, compare 13-fold with MuBax-341/-302 to 1.2-fold and 0.5-fold with MuBax-341/-315 and MuBax-324/-302 respectively). Together these results show that, in

addition to significant sequence conservation (Figure 3), there is functional conservation of the p53 response element in the human and murine *bax* promoters.

To address the significance of the promoter and intronic p53 response elements in the larger context of the murine *bax* gene, a reporter plasmid was made in which the *bax* gene from -898 to +542 was cloned in frame with luciferase (Figure 4A, MuBax). When cotransfected with a p53 expression vector into Saos-2 cells this reporter plasmid was transcriptionally activated (Figure 4A, MuBax). As observed with the human *bax* gene (Figure 2D), there was no significant difference between the p53-dependent transactivation of this reporter as compared to a reporter in which the p53 response element at -339/-304 is deleted (Figure 4A, compare MuBax to MuBax Δ Pr). Deletion of the intronic region containing the newly identified p53 response element, however, produced a reporter construct that was unresponsive to wild-type p53 (Figure 4A, MuBax Δ In). Also, the isolated intron from the murine *bax* gene conferred p53-responsiveness on a minimal promoter, while this same reporter with the p53 response element at +183/+202 deleted did not (Figure 4B). Together, these results demonstrate that this intronic element is required for p53 to mediate transcriptional activation of the murine *bax* gene, as was the case in the human gene.

Discussion

The p53-dependent regulation of Bax expression has been observed in numerous tissues and cell types of the mouse (1,9). Further, Bax has been shown both to be an obligatory downstream

effector for the p53-mediated apoptosis that attenuates choroid plexus tumor growth in the TgT121 mouse model (10), and to function as an effector of p53-dependent apoptosis and a suppressor of oncogenic transformation in mouse embryo fibroblasts (11). Studies showing that the mouse *bax* promoter is not p53 responsive, however, raised the question of whether *bax* is a direct transcriptional target of p53 in the mouse (4,5). In humans, Miyashita and Reed identified a p53 response element in the *bax* promoter (2). Yet, a recent study showed that a reporter containing 1 kb of human promoter sequence failed to respond to p53, further questioning a transcriptional link between p53 and *bax* (4).

The data presented in this report demonstrate the existence of a novel p53 response element in the first intron of the *bax* gene that is perfectly conserved between human and mouse (Figure 1). Further, it is shown that this element is both sufficient and necessary for p53 to mediate transcriptional regulation of the *bax* gene in both species (Figures 2 and 4). In addition, we have demonstrated partial conservation of the p53 response element of the human *bax* promoter in the murine promoter at -339 to -304 (Figures 1B and 3). These results demonstrate that both the human and murine *bax* genes can function as direct transcriptional targets of the tumor suppressor protein p53, and that this response appears to be mediated predominantly through a newly identified response element in the first intron. Thus, these results confirm and substantiate the important role of *bax* as a direct and evolutionarily conserved target of p53-dependent transcriptional activation.

Acknowledgments

We thank Bert Vogelstein (Johns Hopkins University) for the wild-type p53 expression plasmid. Ron Magnusson is thanked for help with the recombinant baculovirus infections. Lois Resnick-Silverman of the Manfredi laboratory is thanked for their help and support. This work was supported by grants from the National Cancer Institute (CA69161) and the Breast Cancer Program of the U.S. Army Medical Research and Materiel Command (DAMD-17-97-1-7336, DAMD-17-97-1-7337, and DAMD-17-99-1-9308).

References

1. Miyashita, T. *et al.* Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. *Oncogene*, 9: 1799-1805, 1994.
2. Miyashita, T. & Reed, J. C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. *Cell*, 80: 293-299, 1995.
3. Thornborrow, E. C. & Manfredi, J. J. One mechanism for cell type-specific regulation of the bax promoter by the tumor suppressor p53 is dictated by the p53 response element. *J Biol Chem*, 274: 33747-33756, 1999.
4. Igata, E. *et al.* Molecular cloning and functional analysis of the murine bax gene promoter. *Gene*, 238: 407-415, 1999.
5. Schmidt, T. *et al.* The activity of the murine Bax promoter is regulated by Sp1/3 and E-box binding proteins but not by p53. *Cell Death Differ*, 6: 873-882, 1999.

6. Resnick-Silverman, L., St Clair, S., Maurer, M., Zhao, K. & Manfredi, J. J. Identification of a novel class of genomic DNA-binding sites suggests a mechanism for selectivity in target gene activation by the tumor suppressor protein p53. *Genes Dev*, 12: 2102-2107, 1998.
7. Baker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K. & Vogelstein, B. Suppression of human colorectal carcinoma cell growth by wild-type p53. *Science*, 249: 912-915, 1990.
8. Tan, T. H., Wallis, J. & Levine, A. J. Identification of the p53 protein domain involved in formation of the simian virus 40 large T-antigen-p53 protein complex. *J Virol*, 59: 574-583, 1986.
9. Bouvard, V. *et al.* Tissue and cell-specific expression of the p53-target genes: bax, fas, mdm2 and waf1/p21, before and following ionising irradiation in mice. *Oncogene*, 19: 649-660, 2000.
10. Yin, C., Knudson, C. M., Korsmeyer, S. J. & Van Dyke, T. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. *Nature*, 385: 637-640, 1997.
11. McCurrach, M. E., Connor, T. M., Knudson, C. M., Korsmeyer, S. J. & Lowe, S. W. bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. *Proc Natl Acad Sci U S A*, 94: 2345-2349, 1997.

Figure Legends

Figure 1. Cloning of the human bax gene reveals a potential p53 response element in the first intron. (A) The human *bax* gene from -571 to +1028 from the start site of transcription was PCR cloned (Accession# AF339054). This region is represented with the black boxes indicating the positions of exons 1 (+373 to +406) and 2 (partial sequence: +991 to +1028). The box labeled p53 RE at -113 to -83 indicates the location of the previously described p53 response element. The sequence of this element and surrounding bases are indicated above. The box labeled p53 RE at +657 to +676 indicates the location of the putative p53 response element located in the first intron. The sequence of this element and surrounding bases are indicated below. The horizontal lines indicate the positions of the p53 quarter sites. The asterisks indicate bases that deviate from the p53 DNA-binding consensus sequence. (B) The murine *bax* gene from -898 to +542 from the start site of translation was PCR cloned (Accession# AF339055). This region is schematically represented with the black boxes indicating the positions of exons 1 (+1 to +34) and 2 (partial sequence: +505 to +542). The white boxes labeled -339 to -304 and +177 to +219 indicate two regions of conservation between the mouse and human sequences. The nucleotide sequences of these two regions is listed. A solid line between the two sequences indicates perfect conservation at that base. Dashed lines indicate a conservative substitution. The boxes indicate the p53 response element half-sites. The asterisks indicate bases that deviate from the p53 DNA-binding consensus sequence. The arrow indicates a cytosine at position -332 that was not reported in the original cloning of the murine *bax* promoter. (C) An electrophoretic mobility shift

assay was performed using an oligonucleotide corresponding to the +657/+676 sequence from the human *bax* promoter as radiolabeled probe. 50 ng of purified p53 was incubated with 3 ng of the probe alone (lane 1) or in the presence of a 500-, 1000-, or 1500-fold molar excess of either the unlabeled HuBax-113/-83 oligonucleotide (lanes 2-4), the HuBax+657/+676 oligonucleotide (lanes 5-7), or the Sens-1 oligonucleotide (lanes 8-10). The arrow indicates the position of the p53-DNA complex.

Figure 2. The first intron of the human bax gene contains a p53 response element that is required for p53-dependent transcriptional activation. (A) Schematic representation of the HuBax, HuBax Δ Pr, HuBax Δ In, Hu+408/+989, Hu+408/+989 Δ In, and HuBax+657/+676 reporter plasmids. Exons are represented by black boxes, and p53 response elements are represented by white boxes. (B) Saos-2 cells were transfected with 1 μ g of the indicated pTATA reporter plasmids in the presence of 0, 1, 5, and 10 ng of pCMV-p53wt. (C) Saos-2 cells were transfected with 1 μ g of the indicated pTATA reporter plasmids in the presence of either 5 ng of pCMV (-) or 5 ng of pCMV-p53wt (+). (D) Saos-2 cells were transfected with 1 μ g of the indicated pGL3 reporter plasmids in the presence of 0, 100, and 200 ng of pCMV-p53wt. Where appropriate, amounts of the vector pCMV were added to each transfection mixture to maintain a constant level of total plasmid DNA (B), (C), and (D). The indicated values are the average of three independent experiments each performed in duplicate. Error bars correspond to one standard deviation. The numbers above each bar indicate the fold activation for each reporter construct

observed with pCMV-p53wt as compared with pCMV.

Figure 3. The p53 response element from the promoter of the human bax gene is conserved in the mouse. (A) Saos-2 cells were transfected with 1 μ g of the indicated pTATA reporter plasmids in the presence of either 50 ng of pCMV (gray bars), 50 ng of pCMV-p53wt (white bars), or 50 ng of p11-4-mup53wt (black bars). The indicated values are the average of three independent experiments each performed in duplicate. The numbers above each bar indicate the fold activation for each reporter construct observed with pCMV-p53wt or p11-4-mup53wt as compared with pCMV. (B) An electrophoretic mobility shift assay was performed using an oligonucleotide corresponding to either the -113/-83 sequence from the human *bax* promoter (bottom panel) or the -341/-302 sequence from the murine *bax* gene (top panel) as radiolabeled probe. 50 ng of purified p53 was incubated with 3 ng of the probe alone (lane 1) or in the presence of a 500-, 1000-, or 1500-fold molar excess of either the unlabeled HuBax-113/-83 oligonucleotide (lanes 2-4), the MuBax-341/-302 oligonucleotide (lanes 5-7), or the Sens-1 oligonucleotide (lanes 8-10). The asterisks indicate the positions of the p53-DNA complexes. (C) Saos-2 cells were transfected with 1 μ g of the indicated pTATA reporter plasmids in the presence of either 50 ng of pCMV (-) or 50 ng of pCMV-p53wt (+). The indicated values are the average of three independent experiments each performed in duplicate. The numbers above each bar indicate the fold activation for each reporter construct observed with pCMV-p53^{wt} as compared with pCMV. The boxes, labeled 1, 2, and 3, indicate the p53 half-sites that are

partially conserved between mouse and human (see Figure 1B).

Figure 4. The first intron of the murine bax gene contains a p53 response element that is required for p53-dependent transcriptional activation. (A) Saos-2 cells were transfected with 1 μ g of the indicated pGL3 reporter plasmids in the presence of either 100 ng of pCMV (black bars) or 100 ng of pCMV-p53^{wt} (white bars). (B) Saos-2 cells were transfected with 1 μ g of the indicated pTATA reporter plasmids in the presence of either 10 ng of pCMV (black bars) or 10 ng of pCMV-p53^{wt} (white bars). (A) and (B) The indicated values are the average of three independent experiments each performed in duplicate. Error bars correspond to one standard deviation. Each reporter insert is diagramed with black boxes representing exons and white boxes indicating p53 response elements.








Fig. 1

A.


pGL3-Basic insert




pTATA insert



B.



C.



D.






Fig. 2

A.



B.



C.




Fig. 3




Fig. 4



DEPARTMENT OF THE ARMY
US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND
504 SCOTT STREET
FORT DETRICK, MARYLAND 21702-5012

REPLY TO
ATTENTION OF:

MCMR-RMI-S (70-1y)

21 Feb 03

MEMORANDUM FOR Administrator, Defense Technical Information
Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir,
VA 22060-6218


SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports written for this Command. Request the limited distribution statement for the enclosed accession numbers be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Kristin Morrow at DSN 343-7327 or by e-mail at Kristin.Morrow@det.amedd.army.mil.

FOR THE COMMANDER:

Encl


PHYLLIS M. RINEHART
Deputy Chief of Staff for
Information Management

ADB263458	ADB282838
ADB282174	ADB233092
ADB270704	ADB263929
ADB282196	ADB282182
ADB264903	ADB257136
ADB268484	ADB282227
ADB282253	ADB282177
ADB282115	ADB263548
ADB263413	ADB246535
ADB269109	ADB282826
ADB282106	ADB282127
ADB262514	ADB271165
ADB282264	ADB282112
ADB256789	ADB255775
ADB251569	ADB265599
ADB258878	ADB282098
ADB282275	ADB232738
ADB270822	ADB243196
ADB282207	ADB257445
ADB257105	ADB267547
ADB281673	ADB277556
ADB254429	ADB239320
ADB282110	ADB253648
ADB262549	ADB282171
ADB268358	ADB233883
ADB257359	ADB257696
ADB265810	ADB232089
ADB282111	ADB240398
ADB273020	ADB261087
ADB282185	ADB249593
ADB266340	ADB264542
ADB262490	ADB282216
ADB266385	ADB261617
ADB282181	ADB269116
ADB262451	
ADB266306	
ADB260298	
ADB269253	
ADB282119	
ADB261755	
ADB257398	
ADB267683	
ADB282231	
ADB234475	
ADB247704	
ADB258112	
ADB267627	